-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
a cancer-fighting drug that blocks blood supply to cancer cells for therapeutic purposes has achieved significant results in human trials,a British medical journal said in a study published ThursdayThe new cancer drug L
-
NNA inhibits the production of an enzyme in the body and reduces the amount of nitric oxide, which helps blood flow to canceroustumor, providing the oxygen and nutrients cancer cells need, according to a study published in the LancetJournal of OncologyAs a result, the drug can eventually "cut off" the blood supply, inhibiting cancer cell growth and divisionThe researchers recruited 18 volunteers in London for the first phase of the human trial, including sevenwomenand 11men, of whom 1
2
were lung cancer patients, five had prostate cancer and one had uterine cancerThe trial found that eight volunteers with large doses of the drug had a sharp reduction in blood content in the of tumors after 1 hour of treatment and were able to maintain 2 4 hours The trial also found possible side effects of L
-
NNA Three patients who participated in the trial had elevated blood pressure after taking the drug and three patients developed palpitations Drug research experts at Mount Vernon Cancer Center say the results of the first phase of human trials are "exciting" to ensure that the new drug makes it to the next phase of larger human trials (
Xinhua News Agency, without permission, it is strictly prohibited to reproduce)
